AUTHORS
Ai-Ni Deng, Sifan Chen2, Yue Pan3, Depei Wu Sr, MD4, Haiping Dai5, Suning Chen, MD, PhD6
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
2 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
3 Servier(Beijing) Pharmaceutical Research and Development Co., Ltd, Beijing, China
4 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
5 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
6 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
ABSTRACT
Background
Relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in acute leukemia (AL) patients with high-risk genetic characteristics including KMT2A rearrangement (KMT2Ar). Menin inhibitors have shown promising activity in relapsed/refractory (R/R) AL as well as in the upfront setting of AL harboring KMT2Ar, NPM1 mutations (NPM1m), or NUP98 rearrangement (NUP98r). However, the efficacy and safety of menin inhibitors when administered post-HSCT remain largely unreported.
Methods
This was a real-world study (NCT07559695). Eligible patients were aged ≥15 with intermediate or high-risk acute leukemia (AL) harboring KMT2Ar, NPM1 mutations (NPM1m) or NUP98 rearrangement (NUP98r). Patients must have received at least 2 cycles of menin inhibitor therapy (7 consecutive days per cycle) or a cumulative treatment duration of ≥14 days, initiated ≥30 days after allo-HSCT. Menin inhibitors included revumenib (innovator or generic formulation) and vicrimenib (BN104/S243249). Patients receiving vicrimenib were enrolled from two prospective studies (NCT06052813 and NCT06746519), with data collection approved by the sponsor (Servier Pharmaceutical Research and Development Co., Ltd). The primary endpoint was relapse-free survival (RFS). Secondary endpoints included overall survival (OS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and adverse events (AEs). All outcome analyses were conducted from the date of first post-HSCT menin inhibitor administration. Adverse events were graded according to CTCAE v5.0.
Survival outcomes were estimated using the Kaplan-Meier method, with 6-month and 1-year landmark rates reported with their corresponding 95% confidence intervals (CIs). CIR and NRM were calculated using cumulative incidence functions to account for competing risks, where NRM was considered a competing event for CIR and vice versa. Statistical significance was set at a two-sided P < 0.05. All analyses were performed using R software.
Results
A total of 21 patients were included in this study. The median age was 40 years (range, 20-65), and 43% were male. Twenty patients were diagnosed with acute myeloid leukemia (AML), and one with T-cell lymphoblastic leukemia/lymphoma. Genetic abnormalities included KMT2Ar in 16 patients (76%), NUP98r in 4 (19%), and NPM1m in 1 (5%). Donor sources included haploidentical (n=16), mismatched unrelated (n=2), matched unrelated (n=2), and matched sibling (n=1). Seventeen patients (81%) underwent allo-HSCT in first complete remission .
Fourteen patients were from NCT06746519 and 4 from NCT06052813, all receiving vicrimenib. Three patients were recruited from real-world practice: 2 received generic revumenib, and 1 received both innovator and generic formulations. The median time to initiate post-HSCT menin inhibitor therapy was 4.14 months (range, 1.18-6.77), with a median treatment duration of 7.56 months (range, 0.36-15.57). Vicrimenib was initiated at 200 mg twice daily, with dose escalation up to 400 mg twice daily in subsequent cycles. Revumenib was started at 50 mg twice daily, with escalation up to 160 mg twice daily. Dose adjustments were implemented for concurrent use of CYP3A4 inhibitors. With a median follow-up of 7.82 months (95% CI, 6.57-14.26), median RFS and OS were not reached (NR; 95% CI, NR-NR). The 6-month and 1-year rates of RFS, OS, and EFS were all 100%. Both 6-month and 1-year CIR and NRM rates were 0%.
The most common adverse events were hematologic toxicities. Grade ≥3 thrombocytopenia, neutropenia, and leukopenia occurred in 48%, 81%, and 48% of patients, respectively, all of which were reversible with temporary treatment interruption and supportive care. Infections were observed in 29% of patients, including upper respiratory tract infection, pulmonary infection, and perianal abscess, with Grade ≥3 events occurring in 5% of patients for each infection type. All infections resolved following appropriate treatment. Epstein-Barr virus reactivation was documented in 14% of patients, all of which were manageable. Cytomegalovirus viremia occurred in one patient and resolved after treatment. No differentiation syndrome or QTc prolongation was observed in any patient.
Conclusion
Post-HSCT maintenance therapy with menin inhibitors demonstrated excellent survival outcomes, zero relapse and non-relapse mortality rates, and manageable toxicity in patients with AL harboring KMT2Ar, NPM1m, or NUP98r.
DISCLOSURES
Haiping Dai: No relevant conflicts of interest to declare.